Oncology Pipeline

Four active molecules spanning discovery through commercialization, organized by modality and lifecycle stage.

Targeted Protein DegradationAntibody-Drug ConjugatesImmuno-OncologyRadioligand TherapyOptimize Portfolio

Pipeline Swim Lane

Molecules by modality category across development stages

Lifecycle Map

All molecules positioned on the 12-stage pharma lifecycle

Active Molecules

Summary cards for each molecule in the Mays portfolio

DT2216
PROTACTarget: BCL-XL

Phase

1/2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
186RNL (Rhenium Obisbemeda)
NanoliposomeTarget: GBM tumors

Phase

1/2

Lifecycle Stage

Stage 4: Phase 2 Clinical

View Details →
Amuvatinib (MP-470)
Small MoleculeTarget: c-Kit/c-Met/PDGFR

Phase

1/2 (completed)

Lifecycle Stage

Stage 4: Phase 2 Clinical

View Details →
753B (BCL-xL/BCL-2 Dual PROTAC)
PROTACTarget: BCL-xL/BCL-2

Stage

Preclinical

Lifecycle Stage

Stage 1: Lead Optimization

View Details →
DT-MCL1 (MCL-1 PROTAC)
PROTACTarget: MCL-1

Stage

Lead Optimization

Lifecycle Stage

Stage 1: Lead Optimization

View Details →
DT-KRAS (KRAS G12D Degrader)
PROTACTarget: KRAS G12D

Stage

Hit-to-Lead

Lifecycle Stage

Stage 0: Target Discovery

View Details →
SF2523 (PI3K+BRD4 Dual Inhibitor)
Small MoleculeTarget: PI3K/BRD4

Stage

IND-Enabling

Lifecycle Stage

Stage 2: Preclinical Development

View Details →
SRX3177 (PI3K+BRD4+CDK4/6 Triple Inhibitor)
Small MoleculeTarget: PI3K/BRD4/CDK4/6

Stage

IND-Enabling

Lifecycle Stage

Stage 2: Preclinical Development

View Details →
CIDD-0149897 (ER-beta Agonist)
Small MoleculeTarget: ER-beta

Stage

Preclinical

Lifecycle Stage

Stage 1: Lead Optimization

View Details →
CIDD99 (Capsazepine-derived)
Small MoleculeTarget: Anticancer

Stage

Preclinical

Lifecycle Stage

Stage 1: Lead Optimization

View Details →
MBD6-targeted (TET2-mutant Myeloid)
PlatformTarget: MBD6/TET2

Stage

Discovery

Lifecycle Stage

Stage 0: Target Discovery

View Details →
Sacituzumab Govitecan (GBM)
ADCTarget: Trop-2

Phase

2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
BSI-082
mAbTarget: SIRPα

Phase

1

Lifecycle Stage

Stage 2: Preclinical Development

View Details →
Imipramine + Lomustine
Small MoleculeTarget: GBM

Phase

2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
Avasopasem (GC4419)
Small MoleculeTarget: SOD mimetic

Phase

1

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
eRapa (Encapsulated Rapamycin)
Small MoleculeTarget: mTOR

Phase

2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
Loncastuximab + Roflumilast + R-CHOP
ADCTarget: CD19

Phase

1b

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
Tislelizumab + SX-682
mAbTarget: PD-1/CXCR1/2

Phase

2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
Tremelimumab + Durvalumab (HCC)
mAbTarget: CTLA-4/PD-L1

Phase

2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
Zanzalintinib + Durvalumab + Tremelimumab (HCC)
Small MoleculeTarget: c-MET/VEGFR/CTLA-4/PD-L1

Phase

2

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
EGCG (Epigallocatechin Gallate)
Small MoleculeTarget: Colon cancer prevention

Phase

Early Phase 1

Lifecycle Stage

Stage 3: Phase 1 Clinical

View Details →
Pluvicto (177Lu-PSMA-617)
RLTTarget: PSMA

Status

Commercial

Lifecycle Stage

Stage 8: Peak Commercialization

View Details →
Pacritinib (Vonjo)
Small MoleculeTarget: JAK2/FLT3

FDA

2022

Lifecycle Stage

Stage 11: Loss of Exclusivity

View Details →
Besremi (Ropeginterferon)
PEG-InterferonTarget: Interferon-alpha

FDA

2021

Lifecycle Stage

Stage 11: Loss of Exclusivity

View Details →
Fedratinib (Inrebic)
Small MoleculeTarget: JAK2

FDA

2019

Lifecycle Stage

Stage 11: Loss of Exclusivity

View Details →
Momelotinib (Ojjaara)
Small MoleculeTarget: JAK1/JAK2/ACVR1

FDA

2023

Lifecycle Stage

Stage 11: Loss of Exclusivity

View Details →
Elacestrant (Orserdu)
Oral SERDTarget: ER

FDA

2023

Lifecycle Stage

Stage 11: Loss of Exclusivity

View Details →